Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Colinz Laboratories Ltd

| Audited Financial Results for the Quarter and Year Ended March 31, 2026

Report Source

⬤29th Apr 26

Summary : Colinz Laboratories reported improved profits and cash flow for FY2026, with an unmodified audit opinion, despite a slight revenue dip.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of Material Consumed (FY26): 57.05 Lakhs
  2. Purchase of Stock in Trade (FY26): 112.48 Lakhs
  3. Employee Benefit Expenses (FY26): 269.56 Lakhs
  4. Finance Cost (FY26): 4.66 Lakhs
  5. Depreciation & Amortisation Expenses (FY26): 15.63 Lakhs
  6. Other Expenses (FY26): 132.26 Lakhs
  7. Revenue from Operation (FY26): 613.61 Lakhs
  8. Other Income (FY26): 48.44 Lakhs
  9. Net Cash from Operating Activities (FY26): 254.11 Lakhs (vs -145.37 Lakhs FY25)
  10. Net Cash from Investing Activities (FY26): 1.13 Lakhs (vs -23.43 Lakhs FY25)
  11. Net Cash from Financing Activities (FY26): 42.66 Lakhs (vs 23.80 Lakhs FY25)
  12. Net increase in Cash and Cash Equivalents (FY26): 297.90 Lakhs (vs -145.00 Lakhs FY25)
  13. Cash and Cash Equivalents at year end (FY26): 852.91 Lakhs (vs 555.01 Lakhs FY25)
  14. Total Assets (Mar 2026): 1278.15 Lakhs (vs 1181.74 Lakhs Mar 2025)
  15. Total Equity (Mar 2026): 1004.31 Lakhs (vs 947.44 Lakhs Mar 2025)
  16. Current Liabilities (Mar 2026): 256.55 Lakhs (vs 216.24 Lakhs Mar 2025)
  17. Cash & Cash Equivalents (Mar 2026): 70.34 Lakhs (vs 240.03 Lakhs Mar 2025)
  18. Other Bank Balances (Mar 2026): 782.57 Lakhs (vs 314.99 Lakhs Mar 2025)
  19. Results are presented on a standalone basis.

Corporate Overview

  1. Primarily engaged in manufacturing Pharmaceutical Formulations.
  2. Formal and compliant with regulatory disclosure requirements.
  3. No other reportable segment besides pharmaceutical formulations.

Risk Factors

  1. Revenue from operations saw a slight decline.
  2. Company relies on single pharmaceutical segment.
  3. No explicit future growth or expansion plans.
  4. Limited information on market competition.

Key Drivers

  1. Strong positive cash flow from operations.
  2. Profit before tax shows good growth.
  3. Overall cash and equivalents significantly increased.

Auditor’s Report

  1. Unmodified opinion on standalone financial results.
  2. Attention drawn to quarterly amounts being balancing figures from annual and nine-month reviewed data.

Corporate Governance

  1. Auditors complied with ICAI's Code of Ethics.
  2. Audit Committee reviewed and recommended financial results.
Dhanarthi

Built With ❤For Indian Investors & Researchers.

With Dhanarthi, stay a step ahead in the market using AI to identify strong stocks and support better financial decisions.

Download AppDhanarthi - AI Driven Stock Insights | Product Hunt

Request an AI Summary of dhanarthi.com

GoogleChatGPTClaudePerplexityGrok

Quick Links

  1. Calculators
  2. Screener
  3. Sectors
  4. Analysis
  5. Blogs
  6. News
  7. Glossary
  8. Pricing
  9. Contact Us

Stay Ahead with the Financial News & Insights

© 2026 Dhanarthi Research House. All Rights Reserved.

Privacy PolicyTerms & ConditionsDisclaimerCookie Policy

Dhanarthi is an AI-powered stock screening, data analytics, and educational research platform. We are NOT a SEBI-registered investment advisor, research analyst, broker, portfolio manager, or financial institution. All data, screening tools, and financial insights are provided strictly for educational and informational purposes to assist in independent research, and should not be construed as personalized investment advice. We do not offer portfolio management, execution of trades, lending services, or guaranteed returns. Investments in the stock market are subject to market risks. Please consult a qualified financial advisor before making any investment decisions.

Colinz Laboratories Ltd (531210) Quarterly Report Analysis & Insights | Dhanarthi